Our review, “Advances in Non-statin Lipid Therapies,” is now published in the American Journal of Cardiovascular Drugs! Read here: https://t.co/9bRi78dPdx DOI: 10.1007/s40256-025-00762-9 Grateful to my co-authors and mentors for their collaboration and support.

Excited to share that two of my first-authored abstracts have been accepted for presentation at AHA 2025, including one selected as a moderated poster. I am grateful to my residency program, coauthors, and mentors for their guidance and support throughout this process. #AHA25

The @ASPCardio 2025 Congress has been an enlightening experience. I’ve gained a deeper appreciation for preventive cardiology and had the privilege to connect with leaders shaping the field. Truly grateful for the meaningful conversations, insights, and inspiration. #ASPC2025

Thinking of joining industry as a preventive cardiologist🫀? 🤌🏻 Best reason to join: passion for drug development ⏰ Best time to join: early in your career 💡 You can work for a company, you can start your own Dr Sergio Fazio discusses his trajectory with a different career

Career phenotypes contd Dr. Sergio Fazio talks industry No slides, just a conversation ✨join early ✨have a passion for drug development ✨join a company, but even better, start your own! @ASPCardio

Dr @RonBlankstein makes the case for linking preventive cardiology and cardiac imaging in your career. The best of both worlds 🫀🤌🏻 : imaging ➡️ convey info to patient that is informative, motivating and actionable #ASPC2025 @ASPCardio @Heart_SCCT

Career Phenotype contd ⭐️Dr. @DBelardoMD talks private practice ✨in-network private practice -⬆️pt accessibility & retention, ⬇️💰barriers, predictable volume ✨concierge practice - pts $ membership fee, 24/7, DPC (pt play monthly fee), fee + insurance (⬆️ access) (1/2)

Career Phenotypes in Prev Cardiology! A timely conversation for me! @ASPCardio 🫀Dr. Nassir talks clinical research @khurramn1 ✨know your why ✨seek answers ➡️ close knowledge gap & improve guidelines ✨build upstream & downstream support ✨a radical idea #powerofzero

Thank you @ASPCardio for this wonderful opportunity to attend the #ASPC2025 Congress as a scholarship recipient! Excited to learn and connect with colleagues and leaders in preventive cardiology. @DrMichaelShapir @ASPCardio

We are so happy to have your with us at @ASPCardio #ASPC2025

Dr Paul Ridker on CLEAR-Synergy: 🫀 Pre vs Post Covid different results? 🫀 Was drug compliance an issue? 🫀 Was site monitoring adequate? Debating the PI of CLEAR-Synergy OASIS Dr @SanjitSJolly! 🔥 #ASPC2025 @ASPCardio #FacesofCVPrevention

Dr Paul Whelton argues that SBP goal should be <120mmHg 🫀 Dr Raymond Townsend thinks - the difference in benefit is much smaller than the difference in risk - we’re already not doing well with 130 - real world is different than clinical trials What are your thoughts?

Debate Time! @ASPCardio Up first, SBP goal < 120 vs < 130 Round 1: Dr. Paul Whelton for Pro < 120 ✨All cause mortality decreases with lower SBP ✨If we shoot for <120 mm we can enhance control rates at <130 and <140 ✨Any additional reduction in BP would be good (1/2)

Dr @SanjitSJolly debating Dr Ridker on colchicine for 2ndary prevention: 🫀 Number of required events was achieved 🫀 Compliance can be explained by diarrhea and side effects 🫀 Cannot infer that different countries have different quality of research Thoughts? 👇🏼 Excellent

Dr Navar in favor of ApoB: ➡️ Apo-B is a better marker of lipid-related risk ➡️ Clinical trials used LDL for inclusion not for endpoint ➡️ Implementing ApoB is not hard #ASPC2025 @ASPCardio

Dr @rblument1 debating Dr Navar against replacing LDL with ApoB 🫀 Clinical Trials and practice have been revolving around LDL 🫀 Confusion with goal numbers 🫀 Cost not explained by benefit @ASPCardio #ASPC2025 #FacesofCVPrevention

💫 Understanding Lp(a): all you need to know @ASPCardio #ASPC2025 @CardioMDPhD @DrMarthaGulati @DrMichaelShapir @LaleTokgozoglu @KronenbergLab @hsbhatia

Round 2: Dr @SanjitSJolly against colchicine ✨the pandemic did not affect results ✨CHANCE was a negative trial ✨CLEAR: Important to not infer things about certain sites #ASPC2025 @ASPCardio

Debate 2 @ASPCardio Colchicine as secondary prevention for coronary disease Round 1: Dr Ridker for colchicine ✨In trials conducted pre COVID… large cardiovascular benefits for a cheap and safe drug! ✨CLEAR-SYNERGY should be looked at cautiously given issues with trial (1/2)

Round 2: @rblument1 is pro LDL-C ✨LDL-C is the primary component of clinical trials & guidelines ✨LDL-C goals are well-established ✨Martin-Hopkins Equation era ✨Selective utility of ApoB ✨Heterogeneity in HLD ✨Failure to diff between varying strengths of atherogenicity